Acarix (ACARIX) investor relations material

Executive summary

• Achieved regulatory approval in the UAE, marking entry into the Gulf region with a strong distribution partner.

• U.S. market drove robust growth in Q2 2026, with 212% revenue increase and broad adoption across care settings.

• Presented positive clinical trial results at ACC.26, validating clinical and commercial value with high negative predictive value and cost/time savings.

• Operating costs decreased by 19% year-over-year, and net loss improved by 26%.

• Cash position strengthened to SEK 28,883 thousand at period end, supported by a SEK 33.4 million directed share issue.

Financial highlights

• Q2 2026 total revenue increased 102% year-over-year to SEK 2,308 thousand; U.S. revenue up 212% to SEK 1,857 thousand.

• Gross margin ranged from 80% to 94% in Q2 2026, with some reports at 84%.

• Operating expenses reduced by 19% year-over-year, from about SEK 14 million to SEK 11.3 million.

• Net loss improved by 26% year-over-year, with Q2 net loss at SEK -9,482 thousand.

• Monthly burn rate reduced by 26.2%, from SEK 4,200 thousand to SEK 3,100 thousand.

Outlook and guidance

• Focus on CPT I transition application, publication of U.S. performance trial, and expanding reimbursement.

• Expects further regulatory approval in Saudi Arabia within 60 days.

• Plans to expand commercial efforts and recurring revenue in the second half of 2026 and beyond.

• Cash position expected to last well into 2027, with potential need for additional financing in Q1 2027.

• Focus on deepening clinical adoption and leveraging the Rural Health Transformation Program for U.S. growth.